47. Ciprofloxacin labeling information includes a boxed warning regarding an increased risk of tendinitis and tendon rupture. What other form of information should be provided to the patient?
Answer: C
A Medication Guide should be provided to the patient.
A Medication Guide is essential to inform patients about the risks associated with taking ciprofloxacin, including the increased risk of tendinitis and tendon rupture. This guide ensures that patients are fully aware of potential side effects and can make informed decisions regarding their treatment.
A) Drug development guide
A drug development guide is not typically provided to patients as it contains detailed information relevant to the research and approval process of the medication rather than practical information about its use or risks. Therefore, it is not suitable for patient education regarding ciprofloxacin.
B) Efficacy information
While efficacy information is important, it does not directly address the specific safety concerns that patients need to be aware of, such as the risk of tendinitis and tendon rupture. Providing efficacy information alone would not fulfill the requirement for adequate patient education in this context.
C) Medication Guide
A Medication Guide is specifically designed to inform patients about the risks and benefits of a medication, including important safety information. In the case of ciprofloxacin, the Medication Guide would highlight the increased risk of tendinitis and tendon rupture, making it the most appropriate form of information to provide to the patient.
D) Prescribing information
Prescribing information is primarily intended for healthcare providers rather than patients. While it contains important details about the medication, it is not formatted or tailored for patient comprehension and does not serve the same purpose as a Medication Guide in conveying essential safety information.
Conclusion
The Medication Guide is the most appropriate information to provide to patients taking ciprofloxacin, as it specifically addresses the safety concerns associated with the drug. Other options, such as a drug development guide or prescribing information, do not effectively communicate necessary risks and benefits to patients, making them inadequate for patient education in this scenario.